Analyst consensus rating
Damora Therapeutics Analyst Rating: Strong Buy
Direct answer
Damora Therapeutics's consensus rating is Strong Buy.
9 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $46.78.
Forecast evidence checked November 13, 2026.
Get free Damora Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $22.05
- Average price target
- $46.78
- High price target
- $59.00
- Low price target
- $40.00
- Low target gap
- +81.4%
- Target upside
- +112.1%
- High target gap
- +167.6%
- Target range width
- 86.2%
- Consensus rating
- Strong Buy
- Analysts
- 9
- Evidence date
- November 13, 2026
- Valid through
- November 20, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Damora Therapeutics?
Damora Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $46.78.
How far are Damora Therapeutics's low and high targets from the recorded price?
The low target implies +81.4%, while the high target implies +167.6%.
How many analysts are included in Damora Therapeutics's consensus?
The verified consensus includes 9 analysts.
How is Damora Therapeutics's target upside or downside calculated?
The average target of $46.78 is divided by the recorded price of $22.05, then one is subtracted to produce +112.1%. This does not guarantee a future return.
When was Damora Therapeutics's analyst forecast verified?
The data was verified on 2026-11-13. The dataset is valid through 2026-11-20.